360 related articles for article (PubMed ID: 27801605)
1. Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches.
Sripichai O; Fucharoen S
Expert Rev Hematol; 2016 Dec; 9(12):1129-1137. PubMed ID: 27801605
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional silencing of fetal hemoglobin by BCL11A.
Sankaran VG; Xu J; Orkin SH
Ann N Y Acad Sci; 2010 Aug; 1202():64-8. PubMed ID: 20712774
[TBL] [Abstract][Full Text] [Related]
3. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
[TBL] [Abstract][Full Text] [Related]
4. Genomic approaches to identifying targets for treating β hemoglobinopathies.
Ngo DA; Steinberg MH
BMC Med Genomics; 2015 Jul; 8():44. PubMed ID: 26215470
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation of Krüppel-like factor 1 (KLF1) and fetal hemoglobin (HbF) levels in β
Khamphikham P; Sripichai O; Munkongdee T; Fucharoen S; Tongsima S; Smith DR
Int J Hematol; 2018 Mar; 107(3):297-310. PubMed ID: 29067594
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
Watanapokasin R; Sanmund D; Winichagoon P; Muta K; Fucharoen S
Ann Hematol; 2006 Mar; 85(3):164-9. PubMed ID: 16389564
[TBL] [Abstract][Full Text] [Related]
7. Targeting fetal hemoglobin expression to treat β hemoglobinopathies.
Steinberg MH
Expert Opin Ther Targets; 2022 Apr; 26(4):347-359. PubMed ID: 35418266
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.
Lohani N; Bhargava N; Munshi A; Ramalingam S
J Cell Physiol; 2018 Jun; 233(6):4563-4577. PubMed ID: 29159826
[TBL] [Abstract][Full Text] [Related]
9. Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia.
Breda L; Rivella S; Zuccato C; Gambari R
Expert Rev Hematol; 2013 Jun; 6(3):255-64. PubMed ID: 23782080
[TBL] [Abstract][Full Text] [Related]
10. Structural and Functional Insights on an Uncharacterized Aγ-Globin-Gene Polymorphism Present in Four β0-Thalassemia Families with High Fetal Hemoglobin Levels.
Bianchi N; Cosenza LC; Lampronti I; Finotti A; Breveglieri G; Zuccato C; Fabbri E; Marzaro G; Chilin A; De Angelis G; Borgatti M; Gallucci C; Alfieri C; Ribersani M; Isgrò A; Marziali M; Gaziev J; Morrone A; Sodani P; Lucarelli G; Gambari R; Paciaroni K
Mol Diagn Ther; 2016 Apr; 20(2):161-73. PubMed ID: 26897028
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia.
Uda M; Galanello R; Sanna S; Lettre G; Sankaran VG; Chen W; Usala G; Busonero F; Maschio A; Albai G; Piras MG; Sestu N; Lai S; Dei M; Mulas A; Crisponi L; Naitza S; Asunis I; Deiana M; Nagaraja R; Perseu L; Satta S; Cipollina MD; Sollaino C; Moi P; Hirschhorn JN; Orkin SH; Abecasis GR; Schlessinger D; Cao A
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1620-5. PubMed ID: 18245381
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients.
Watanapokasin Y; Chuncharunee S; Sanmund D; Kongnium W; Winichagoon P; Rodgers GP; Fucharoen S
Exp Hematol; 2005 Dec; 33(12):1486-92. PubMed ID: 16338491
[TBL] [Abstract][Full Text] [Related]
13. Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.
Bauer DE; Orkin SH
Curr Opin Genet Dev; 2015 Aug; 33():62-70. PubMed ID: 26375765
[TBL] [Abstract][Full Text] [Related]
14. Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β
Cosenza LC; Zuccato C; Zurlo M; Gambari R; Finotti A
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292612
[TBL] [Abstract][Full Text] [Related]
15. Polymorphic variations influencing fetal hemoglobin levels: association study in beta-thalassemia carriers and in normal individuals of Portuguese origin.
Pereira C; Relvas L; Bento C; Abade A; Ribeiro ML; Manco L
Blood Cells Mol Dis; 2015 Apr; 54(4):315-20. PubMed ID: 25842369
[TBL] [Abstract][Full Text] [Related]
16. Modifying effect of XmnI, BCL11A, and HBS1L-MYB on clinical appearances: A study on β-thalassemia and hemoglobin E/β-thalassemia patients in Indonesia.
Rujito L; Basalamah M; Siswandari W; Setyono J; Wulandari G; Mulatsih S; Sofro AS; Sadewa AH; Sutaryo S
Hematol Oncol Stem Cell Ther; 2016 Jun; 9(2):55-63. PubMed ID: 27009595
[TBL] [Abstract][Full Text] [Related]
17. An Aγ-globin G->A gene polymorphism associated with β
Breveglieri G; Bianchi N; Cosenza LC; Gamberini MR; Chiavilli F; Zuccato C; Montagner G; Borgatti M; Lampronti I; Finotti A; Gambari R
BMC Med Genet; 2017 Aug; 18(1):93. PubMed ID: 28851297
[TBL] [Abstract][Full Text] [Related]
18. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A.
Sankaran VG; Menne TF; Xu J; Akie TE; Lettre G; Van Handel B; Mikkola HK; Hirschhorn JN; Cantor AB; Orkin SH
Science; 2008 Dec; 322(5909):1839-42. PubMed ID: 19056937
[TBL] [Abstract][Full Text] [Related]
19. Fetal Hemoglobin Regulation in Beta-Thalassemia.
Lu HY; Orkin SH; Sankaran VG
Hematol Oncol Clin North Am; 2023 Apr; 37(2):301-312. PubMed ID: 36907604
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of Fetal Hemoglobin for Treating β-Thalassemia and Sickle Cell Disease.
Cui S; Engel JD
Adv Exp Med Biol; 2017; 1013():177-202. PubMed ID: 29127681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
